लैम्बॉर्गिनी का 2023 में भारतीय बाजार में ‘शतक’ लगाने का इरादा
HE MISSED HIS PREFERRED EXIT AGE BY JUST ONE YEAR – THISDAYLIVE
Guitarist Tom Verlaine, Co-Founder of Punk-Era Band Television, Dies at 73 – NBC Connecticut
Holly Ramer/Associated Press
The Linux Foundation Reflects on Open Source's Role in Climate Change Challenges
Iowa Democratic Party elects Rita Hart as new chair
Shooting at Massachusetts mall leaves 'innocent bystander' dead, suspect in custody
Non-Profit Thrift Store Provides Resources To Formerly Incarcerated Women
State Police seek suspect after stabbing incident in South Middleton Township Friday
Library Friends Big Winter Book Sale Ends Today With $7 Bag Sale
Bath Road Esso: Brand new petrol station, Greggs and Costa opens
McLaughlin water bottle issue causes Daytona setback
Ravensburger Reveals Marvel Villainous
Have you seen this missing teen from Joplin, Mo.
Broncos, Jim Harbaugh follow-up meeting didn't result in deal
Scientists observe warming seas for harmful algal blooms
Matt Taibbi says the Left's source for Russian disinformation bots were accounts of 'real Americans'
Payback is hell and as we say, Karma! – Windows to Russia
Equal Marks For Descriptive, Objective Papers In Class X Boards
Coast Bus loses bid to stop KRA Sh28m tax demand
Archie's Valentine's Day Spectacular 2023 Preview
Genelux Corporation Announces Pricing of Initial Public Offering
25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux” or “the Company”), a clinical-stage immunotherapy company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types, today announced the pricing of its initial public offering of 2,500,000 shares of its common stock at a price to the public of $6.About Genelux Corporation Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.4912 p Source: Genelux Corporation Serious News for Serious Traders!In addition, Genelux has granted the underwriters a 30-day option to purchase up to an additional 375,000 shares of its common stock at the initial public offering price less the underwriting discounts and commissions.
Forward-Looking Statements This press release contains statements that constitute “forward-looking statements,” including with respect to the proposed initial public offering.Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Genelux, including those set forth in the Risk Factors section of Genelux’s registration statement for the initial public offering filed with the SEC.